|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Asthma
This debilitating condition is caused by narrowing and inflammation of the airways in the lungs; symptoms include recurrent attacks of wheezing, coughing, shortness of breath, and labored breathing. The frequency of asthma has been increasing for all age groups.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Asthma Study CIGE025A2432
The purpose of this clinical trial is to find out if the drug omalizumab (Xolair®) has beneficial effects on the airways in people who have moderate to severe allergic asthma. Xolair® has been approved in the European Union and by the U.S Food and Drug Administration for the treatment of persistent allergic asthma.
Trial phase: Phase 4 Participation Duration: Participation in the study will last approximately one and a half years. During that time, participants will be asked to visit the study center to receive subcutaneous (under the skin) injections of study medication and assessments. Protocol Number: CIGE025A2432 Persistent Allergic Asthma Trial CIGE025AUS33
The purpose of this clinical research study is to determine if the drug omalizumab (Xolair®) has safe and helpful effects in people who have inadequately controlled persistent allergic asthma. This study is a double-blind placebo study. It is important to note, you may receive omalizumab (Xolair®) OR a placebo (a dummy drug with no active ingredients). Xolair® is approved by the US Food and Drug Administration (FDA) for the treatment of allergic asthma in adults and adolescents 12 years of age and older and is already available for sale in the United States.
Trial phase: Phase 4 Participation Duration: This is a 26 week study. Adult participants or participating children (at least 12 years of age or older) and their parent or caregiver will be required to take part in a 2 week screening process. Participants passing the screening process will be eligible to participate in the study for an additional 24 weeks, where they will be required to visit the study center every 2 to 4 weeks to receive treatments by injection. Protocol Number: CIGE025AUS33 |